3 completed, 3 unknown, 1 enrolling by invitation. 4 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 1 | 3 | Unknown 3 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Artgen Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2 Betuvax-CoV-2, Placebo - COVID-19 | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 116 | 2021-10-14 | 2022-03-08 |
| Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF Dysferlinopathy, Miyoshi Myopathy | Enrolling by invitation | Artgen Biotech | 100 | 2020-01-15 | 2025-06-27 | |
| Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot Neovasculgen - Ulcers Related to Diabetic Foot Syndrome | Not applicable | Completed | Artgen Biotech | 35 | 2015-08-01 | 2017-04-05 |
| Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury Neovasculgen - Peripheral Nerve Injury | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 45 | 2015-04-01 | 2015-02-02 |
| Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Neovasculgen - Secondary Raynaud's Phenomenon | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 30 | 2015-03-01 | 2015-02-05 |
| Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia Neovasculgen® - Lower Limb Ischemia | Phase 4 | Completed | Artgen Biotech | 210 | 2012-09-01 | 2017-02-28 |
| Efficiency, Safety and Portability of Neovasculgen Neovasculgen (Cambiogeneplasmid) - Peripheral Arterial Disease | Phase 2 / Phase 3 | Completed | Artgen Biotech | 100 | 2010-02-01 | 2017-03-03 |
COVID-19 (1) · Coronavirus Infections (1) · Dysferlinopathy (1) · Ischemia (1) · Limb-girdle muscular dystrophy, type 2B (1) · Miyoshi myopathy (1) · Peripheral Arterial Disease (1) · Peripheral Nerve Injuries (1) · Raynaud Disease (1) · Scleroderma, Systemic (1) · Trauma, Nervous System (1) · Ulcer (1)
Saline Solution (1)
Russia (6)
Roman Deev, PhD (1) · Roman V Deev, MD (1)
PMID 25770117, PMID 29996720, PMID 35047756, PMID 36851204, PMID 37553796, PMID 38365661, PMID 39973465